implicated in force transduction across breast cancer subtypes. Peyton said subtype-specific migration and proliferation of cancer cells depends on the ability of cells to activate force transduction pathways and generate intracellular tension. She said highthroughput biochemical signaling analysis techniques will be used to measure activation of key pathways implicated in force transduction and cytoskeletal assembly.
Her third objective is to build statistical models to discover signals that contribute to metastasis across combinations of cell type and extracellular matrix (ECM) composition. "Correlations between cell signaling and measured markers of metastasis exist and are detectable using a multivariable statistical framework," said Peyton. "Multivariable models based on robust statistical methods will be used to relate cell type, ECM composition, and signaling nodes contributing to cell migration, proliferation, and, therefore, poor patient prognosis."
Leonid Hanin, Ph.D., professor of mathematics and statistics at Idaho State University in Pocatello said he does not expect major breakthroughs from the engineering approaches to cancer, although some ideas and results may be useful. "Physical properties of cancer cells change with cell type and stage of cancer, so these differences and changes can be detected using the methods of engineering. What I like about the involvement of engineers, as well as mathematicians and physicists, in cancer studies is that they bring in an entirely different frame of thinking, which is so much different from that of biomedical scientists."
Hanin said although basic cancer biology and clinical oncology generated over the last several decades an enormous body of knowledge, its translational value is very small. "Most importantly, and ominously, cancer incidence and mortality for most types of cancer remain very high, and for some of them mortality continues to rise.
Michael Sheetz, Ph.D., director of the Mechanobiology Institute of Singapore, said we can expect to see engineering and other research disciplines-besides more "traditional medicine"-tackling tough issues such as metastasis and other aspects of cancer in the future. "The problem with most cancers is that the cells do not respond properly to the cues from the local microenvironment, and therefore, cancer cells need to be understood in terms of their 'mechanobiology'. The question is, how does a cancer cell avoid mechanical cues that should block its growth? That question cannot be answered with just biochemistry." Sheetz is also the William R. Kenan Jr. professor of cell biology at Columbia University in New York.
Hanin offered an important caveat about swinging too far into the mathematical-engineering camp of cancer research. "Another concern of mine is that designing mathematical models by engineers and their doing statistical analysis may be a recipe for disaster. This should be done by professional mathematicians and statisticians. I have read and reviewed hundreds of papers involving mathematical modeling and statistical data analysis, and in about 70% of cases what was done is totally wrong."
Peyton has established safeguards to ensure that does not happen. "Data of high confidence will be consistently produced, via collaboration between a completely experimental lab and one that focuses on developing and implementing statistical models and methods," she said. Lead author Ethan Halpern, M.D., codirector of Jefferson's Prostate Diagnostic Center, said as a result of the study, they found almost three times as many highergrade cancers by using half as many needle biopsies compared with systematic biopsy methods. "Today, a physician may sample 12-18 tissue cores from the prostate in order to help diagnose a patient. But with contrast-enhanced, that number drops to six or even less," said Halpern. "As a result, we believe CEUS could prove to be more efficient for screening clinically important cancers and monitoring low-risk ones with fewer biopsies." CEUS has been studied before. Two smaller studies, both conducted by researchers from the Medical University in Innsbruck, Austria-one in 2007 and the second in 2010-also concluded that CEUS improved prostate cancer detection. "Our study similarly confirms an increased frequency of positive cores in CEUStargeted biopsy compared to systematic biopsy by nearly double," said Halpern (16.4% vs. 8.5%.). Ultrasound is one of the two main imaging methods used for prostate cancer detection. Multiparametric magnetic resonance imaging (MRI) is also being tested in this context and has shown promise. Loeb said multiparametric MRI has been associated with both the presence and extent of prostate cancer on biopsy. "MRI has also been shown to predict the likelihood of shortterm progression on active surveillance."
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By contrast, ultrasound imaging of the prostate is commonly used to assess the size of the gland and for needle placement during systematic biopsy, but it cannot easily distinguish benign from malignant tissue. Halpern believes CEUS could change that.
Surprise Discovery
History is replete with inadvertent discoveries that turn out better than what was originally sought. The same is true of the Jefferson study. "The result of this study was a pleasant surprise," said Halpern, who explained that the original goal of the study was to investigate whether an oral dutasteride pretreatment improved the detection of prostate cancer. "It was a randomized study to look at that." Although dutasteride had no effect, the researchers were pleased to find that CEUS-targeted biopsy provides a significant benefit for the detection of high-grade/high-volume prostate cancer.
A total of 272 men (210 white, 54 black, 6 Hispanic, and 2 Asian) completed the randomized, double-blind, placebo-controlled trial. Their mean age was 62 years (range, 36-83 years), with mean serum PSA levels of approximately 6.5 ng/dL.
Before contrast administration, grayscale ultrasound was performed to measure gland size and to evaluate for focal echo texture and contour abnormalities. The contrast agent along with 50 mL of normal saline was administered via an intravenous line in each subject's arm for 10 minutes. The contrasting agent used was perflutren lipid microsphere a nonpyrogenic suspension of liposome-encapsulated perfluoropropane microbubbles. "There are other agents that can be used as well," said Halpern. Subjects were imaged in the lithotomy position to minimize perturbation of vascularity measurements.
Precontrast color and power Doppler imaging were performed to evaluate blood flow. During contrast infusion, continuous harmonic gray-scale imaging was performed, followed by color and power Doppler imaging, intermittent gray-scale harmonic imaging with a 2-second interscan delay, and finally flash replenishment imaging coupled with maximum-intensity projection imaging. Halpern said that prostate cancer, especially higher-grade cancers, have increased and disorganized pattern of microvessel density that can be observed using flash replenishment imaging. "It allows us to see if there is more blood flow and if there is an unusual pattern that could be associated with cancer."
The contrastenhanced ultrasound findings were graded and used to direct targeted biopsy (up to six cores per prostate). A blinded 12-core systematic biopsy was then performed on every subject on the basis of standard medial and lateral sampling of each sextant.
Positive biopsy samples indicating prostate cancer were found in 43% of the men. The researchers found mean PSA of patients with and those without prostate cancer was not significantly different (7.1 vs. 6.4 ng/dL). For the detection of high-grade cancer (Gleason score 7 or greater,) receiver operating characteristic (ROC) analysis demonstrated improved accuracy for precontrast imaging and contrast-enhanced ultrasound. For the detection of highgrade cancer with greater than 50% biopsy core involvement, the researchers reported that excellent accuracy was demonstrated with precontrast and contrast-enhanced ultrasound.
Halpern has no illusions that CEUS is the be-all, end-all of prostate cancer detection. He noted that the combination of gray-scale with CEUS imaging provides an ROC area of only 0.64, suggesting that this technique misclassifies many cases. "Also, the paired analysis of CEUS targeted versus systematic biopsy confirms that CEUS misses many cancers."
Still, Philip Kantoff, M.D., vice chair of department of medical oncology and professor of medicine at Harvard Medical School, said the study did a very good job of demonstrating the potential value of CEUS in the detection of high-grade prostate cancer, "which is the type of cancer we need to detect." Kantoff added that the findings need to be confirmed in larger, multi-institutional studies.
Kantoff said the study has the potential to erase a lot of doubt over screening and monitoring. "Current biopsy techniques for the detection of prostate cancer are woefully inadequate," said Kantoff. "They are essentially blind biopsies guided by ultrasound, which simply allows imaging of the configuration of the gland to allow systematic but random biopsy. Better imaging techniques are needed and will probably reduce the number of unnecessary biopsies and enhance the detection of potentially lethal prostate cancer." 
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Without question, adding imaging studies before biopsy could increase costs. "However, these increased up-front costs might be warranted if the use of imaging ultimately reduces unnecessary biopsies and treatment," said Loeb.
CEUS and Active Surveillance
It is widely accepted that older men, or men who have other serious health problems, may never need treatment for prostate cancer. This was a large part of the concern expressed by the U.S. Preventive Services Task Force. Instead, they may benefit from active surveillance, where their cancers are monitored with various tests to determine whether the cancer is beginning to be more aggressive.
"It stands to reason that the cost-benefit ratio for prostate cancer screening will improve if PSA screening is followed by a limited targeted biopsy based on CEUS," The PDQ Genetics of Skin Cancer sum mary was recently updated to include the results of the Genes, Environment, and Melanoma (GEM) study, a multicenter, population-based, case-control study. The study showed that first-degree relatives of CDKN2A mutation carriers with melanoma had an approximately 50% increased risk of cancers other than melanoma compared with first-degree relatives of other melanoma patients. Cancers with increased risk in this population included gastrointestinal cancers (relative risk [RR] , 2.4; 95% CI, 1.4-3.7), pancreatic cancers (RR, 7.4; 95% CI, 2.3-18.7), and Wilms tumor (RR, 40.4; 95% CI, . This study provides further evidence that CDKN2A mutations are associated with increased risk of several cancers other than melanoma. The PDQ Chronic Myeloproliferative Disorders Treatment summary was recently updated to include information about ruxolitinib, an inhibitor of the Janus kinases JAK1 and JAK2 that helps reduce the splenomegaly and debilitating symptoms of weight loss, fatigue, and night sweats in patients with JAK2-positive or JAK2-negative primary myelofibrosis, post-essential thrombocythemia myelofibrosis, or post-polycythemia vera myelofibrosis. The summary was also updated to include results from two prospective, randomized trials with a total of 528 higherrisk patients who were randomly assigned to ruxolitinib or best available therapy or placebo. In the trial with best available therapy as the control arm, patients on ruxolitinib had a decrease of 56% in mean palpable spleen length at 48 weeks compared with an increase of 4% with best available therapy. In the placebo-controlled trial, 41.9% of patients on ruxolitinib had a >35% reduction in spleen volume at 24 weeks compared with 0.7% of patients on placebo. Ruxolitinib also improved overall quality-of-life measures, with low toxic effects in both studies but with no benefit in overall survival. Discontinuation of ruxolitinib resulted in a recurrence of systemic symptoms. http://www.cancer.gov/cancertopics/pdq/ treatment/myeloproliferative/Health Professional/Page4#Section_243 The PDQ Screening and Prevention Editorial Board recently completed a major update of the Ovarian Cancer Screening summary. The Board conducted a review of the published literature and revised the text of the summary and updated the citations. To review the summary, please use the following link: http://www.cancer.gov/cancertopics/pdq/ screening/ovarian/HealthProfessional The PDQ Complementary and Alterna tive Medicine Editorial Board published a new summary about the use of high-dose vitamin C as a treatment for people with cancer. A comprehensive review of published literature was performed and the summary was reviewed by external experts in the field before final approval by the Editorial Board. The summary was posted on Cancer.gov on 02/08/2013. To review the summary, please use the following link: http://www.cancer.gov/cancertopics/pdq/ cam/highdosevitaminc/healthprofessional/ page1/AllPages
